TWO · 6748.TWO
ACRO Biomedical Co., Ltd.
NT$182.50-NT$11.50 (-5.93%)
ACRO Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.13% below the high.
Loading market information…
TAI · 1752.TW · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Nang Kuang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.04% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Nang Kuang Pharmaceutical Co., Ltd.’s forward annual dividend is NT$1.60 per share, paid annual. The forward yield is 5.32% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Nang Kuang Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of NT$0.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nang Kuang Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Primarily based in Taiwan, Nang Kuang Pharmaceutical Co., Ltd. functions as a pharmaceutical enterprise. Its comprehensive product range includes various sterile injectable forms such as parenterals, aseptic parenterals, lyophilized injections, pre-filled syringes, and pre-mixed intravenous (IV) infusion bags. Additionally, it manufactures conventional dosage forms like tablets, capsules, oral suspensions, and topical applications. The company's offerings span a wide array of therapeutic categories, including treatments for cardiovascular, gastrointestinal, and nervous system disorders; alimentary and metabolic conditions; blood-related issues; antineoplastic and immunomodulatory agents; musculoskeletal and respiratory ailments; dermatological concerns; genito-urinary and sex hormone therapies; systemic hormones; and systemic antibacterials. Nang Kuang also supplies cosmetic products and comprehensive hospital solutions. Furthermore, Nang Kuang specializes in advanced pharmaceutical technologies, producing sterile and anticancer injectable products, controlled-release formulations (both injectable and oral), and oral disintegrating tablets. Founded in 1963, Nang Kuang Pharmaceutical Co., Ltd. is headquartered in Tainan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:28 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| NT$579.48M-3.42% vs estimate |
| Q4 2024 | Feb 20, 2025 | NT$0.570.0% vs estimate | NT$572.00M0.0% vs estimate |
|---|
| Q3 2024 | Nov 8, 2024 | NT$0.58-33.33% vs estimate | NT$580.00M-3.33% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$182.50-NT$11.50 (-5.93%)
ACRO Biomedical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.13% below the high.
NT$65.60+NT$5.30 (+8.79%)
Bionime Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.01% below the high.
NT$43.50-NT$0.30 (-0.68%)
Orient EuroPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$27.95-NT$0.45 (-1.58%)
BRIM Biotechnology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.34% below the high.
NT$69.00-NT$0.50 (-0.72%)
ICARES Medicus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 16.9% below the high.
NT$76.80+NT$0.30 (+0.39%)
SYN-TECH Chem. & Pharm. Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.42% below the high.
NT$35.10-NT$1.00 (-2.77%)
Maxigen Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.33% below the high.
NT$32.00-NT$0.60 (-1.84%)
Energenesis Biomedical CO.,LTD.’s quoted price sits in the lower half of its reported 52-week range, 46.4% below the high.
